Ventegis Capital
Kurfürstendamm 119, Berlin, 10711, Germany
Overview
The Ventegis Capital AG in 2001 emerged from the merger of the Berlin AG Beteiligungsgesellschaft effect on the Cybermind AG. Both companies have been in private equity / venture capital activity. As a publicly traded venture capital company, they invest the money of their shareholders. The activities of the Ventegis are divided into two business segments. In addition to the venture capital business since 2002 consulting services offered. In the venture capital business Ventegis belongs to the smaller players on the German market. As a reliable and active partner, they position themselves as a typical lead-as well as co-investors. Here they prefer to consortia consisting of renditeorientieren and strategic investors. In future, the market position through further Neuinvestments expanded. Crucial for a commitment of Ventegis are the yield potentials of our investments, which in the past the focus of investment activity on early-stage financing traditionally stood.
- Total investments
- 3
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- Humedics
Participated · Series C · Nov 2014
Humedics has developed the LiMAx breath-test diagnostic system, which comprises a CE-marked medical device, breath masks and a diagnostic drug to quantitatively determine individual liver function within minutes. The test enables clinicians to tailor treatment strategies based on a patient’s liver capacity. Current applications include assessment before and after liver transplantation, liver surgery planning to evaluate resection risk, and evaluation of diseases such as liver cirrhosis. The company is led by Managing Director Erwin de Buijzer and is based in Berlin, Germany. Humedics closed a €6.3m Series C financing round to support its next stage of growth. The proceeds are intended to fund the European market entry of the LiMAx test and the corresponding FLIP diagnostic device. Humedics develops a proprietary, CE-marked diagnostic system (the LiMAx test) that quantitatively determines individual liver function capacity within minutes. The system comprises the FLIP medical device and an intravenous diagnostic drug preparation (13C-Methacetin). Current applications include assessment before and after liver transplantation, planning of liver surgeries, and evaluation of liver diseases such as cirrhosis. The company completed its first venture financing round to support final development and early commercialization. The amount raised was undisclosed; management intends to deploy the funds to finish development and begin commercial rollout. Humedics is led by Dr. Klaus Stöckemann (Chairman) and Managing Director Wilfried Heyne and is based in Berlin, Germany. Humedics commercializes an innovative method for instantaneous measurement of liver function at the patient’s bedside. The newly formed spin-off from Freie Universität Berlin and the Charité university hospital is based in Grossbeeren, Germany. The company plans to develop production devices and pursue regulatory approval for its bedside liver-function measurement technology. Humedics received a €500,000 investment from High‑Tech Gründerfonds to begin development and the approval process. The funds are earmarked to start production-device development and the regulatory filings required for clinical use. No revenue, user, or other operating metrics were disclosed in the article.
- SulfurCell
Participated · Equity · Jan 2011
Sulfurcell develops, manufactures and sells CIGS/CIGSe thin‑film photovoltaic modules and building-integrated PV solutions for BIPV, solar construction and commercial rooftops. The company has commercialized at scale since shipping its first modules in 2005 and is ramping up a 35 MW production facility. Sulfurcell reports manufacturing full‑scale thin‑film modules at 12.6% efficiency and is targeting 14% efficiency within 12–18 months through ongoing R&D. The company employs about 250 people and has developed an automated industrial manufacturing process for its second‑generation thin‑film technology. Sulfurcell was founded in 2001 as a spin‑off from the Helmholtz Centre for Materials and Energy and has received multiple rounds of growth financing to support production and R&D, including a prior €85m round used to build a Berlin production facility. The recent equity raise will fund expansion and market introduction of its second‑generation CIGSe PV technology.
- Nanda Technologies
Participated · Equity · May 2010
Nanda Technologies develops a high-throughput full-wafer inspection system used in semiconductor manufacturing, based on a proprietary optical design and image-processing software. Its technology increases inspection speed while maintaining high sensitivity, enabling inspection of every wafer in the process flow rather than sampling. The approach materially lowers inspection cost per wafer compared with existing tools. The company is based in Unterschleissheim, Germany. Nanda will use the recent financing to support pre-production evaluations at leading semiconductor manufacturers. Capital-E will take an active board role to support the company’s further growth.
Team
No current team members are available.